Navigation Links
Neogen Develops Quickest Single Test for Beta-Lactams and Tetracyclines in Milk
Date:4/27/2009

LANSING, Mich., April 27 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) has expanded its line of products developed for the worldwide dairy industry to include the quickest single test available to simultaneously detect beta-lactam and tetracycline antibiotic residues in milk.

Developed to comply with the European Union's maximum residue levels, Neogen's new BetaStar(R) Combo utilizes the same format as the popular BetaStar assay -- an extremely easy lateral flow test that requires only minimal training and equipment to produce consistently accurate results. At just 5 minutes, BetaStar Combo is the fastest assay for beta-lactams and tetracyclines in a single test.

"As the use of both tetracycline and beta-lactam antibiotics for the management of mastitis in dairy herds has grown in certain regions of the world, the need for a single test to simultaneously detect both groups of antibiotics has also grown," said Ed Bradley, Neogen's vice president of Food Safety. "Developing BetaStar Combo allows us to offer the worldwide dairy industry yet another simple solution to protect its consumers and businesses. Neogen can now offer the dairy industry rapid, easy tests to detect either beta-lactam or tetracycline antibiotics, or both at the same time, in the same simple test format."

The BetaStar Combo test method is easy to use and is also very rugged -- making the test effective for use in the milk receiving laboratory, on the truck, or even at the farm level.

The tetracycline group of antibiotics is not as widely used as the beta-lactam group; therefore, testing for tetracycline residues in milk is not as widespread. The European Union has set a maximum residue level of 100 parts per billion for tetracyclines in milk and Neogen expects the strongest initial interest for its BetaStar Combo pro
'/>"/>

SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neogen Reports Record Third Quarter
2. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results Conference Call
3. NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results
4. NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009
5. Neogen Names New Senior Science Officer; Added to S&P Index
6. Neogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry
7. Neogens BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS
8. Neogen Reports Best Quarter in Its 26-Year History
9. Neogen Announces New Share Repurchase Program
10. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
11. Neogen Honored by Forbes; Two Brokerage Firms Initiate Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... 26 Advanced Life Sciences Holdings, ... in the discovery, development and commercialization of novel drugs in ... announced positive results from in vitro and ... its novel oral antibiotic, against the species of Plasmodium ...
... ... be responsible for leading the MM-121 research team through Development and creating the Company’s ... ... held biotechnology company focused on the discovery and development of novel treatments for cancer ...
... MORRISTOWN, N.J. , May 25 ... confirmed that its subsidiary, Watson Laboratories, Inc. filed an ... and Drug Administration (FDA) seeking approval to market sevelamer ... generic version of Genzyme,s Renvela®.  Renvela ® is a ...
Cached Biology Technology:Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 2Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 3Watson Confirms Renvela® Patent Challenge 2Watson Confirms Renvela® Patent Challenge 3
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2
... in German . , The detector ... has a very low error rate. The results have ... Ultrafast, efficient, and reliable single-photon detectors are among the ... have not yet reached maturity for practical application. Physicist ...
... Caroline Leck of Stockholm University has evaluated the Norwegian ... sensational," says Dr Leck. "If confirmed by other studies, ... the political targets for climate." Temperature rise ... temperature climbed sharply through the 1990s, the increase has ...
... Daubenton,s bat, the attractions of family life seem to vary ... sex. For more than a decade, a team led ... of Biology has studied a population of several hundred bats ... roosts in Ilkley and Addingham, upstream in the market town ...
Cached Biology News:Quantum communication: Each photon counts 2Global warming less extreme than feared? 2Global warming less extreme than feared? 3Global warming less extreme than feared? 4Bats split on family living 2Bats split on family living 3
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Biology Products: